SCHEDULE: Susquehanna Discloses 5.2% Stake in Purple Biotech
Beneficial Ownership Report
Susquehanna Securities, LLC has reported a 5.2% beneficial ownership stake in Purple Biotech Ltd., holding 93.95 million ordinary shares.
Summary
- Susquehanna Securities, LLC has filed a Schedule 13G, disclosing beneficial ownership of Purple Biotech Ltd.'s Ordinary Shares.
- The reporting person holds 93,953,400 Ordinary Shares, which represents 5.2% of the company's outstanding class.
- This ownership is comprised of 469,767 American Depositary Shares (ADSs), with each ADS representing 200 Ordinary Shares.
- The filing indicates the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Purple Biotech Ltd. had 1,806,089,801 Ordinary Shares outstanding as of October 20, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of a passive ownership stake and does not contain new operational or financial information about the company.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are standard disclosures for passive investors who acquire more than 5% of a company's voting class of securities. This filing indicates Susquehanna Securities, LLC's position as a significant, but passive, shareholder in Purple Biotech Ltd., a common occurrence for institutional investors in the biotech sector.
Stakeholder Impact
- Shareholders: Awareness of a new significant institutional investor holding a passive stake.
- Investors: Provides transparency regarding institutional ownership structure.
Key Dates
| Date | Description |
|---|---|
| 2025-10-20 | Date Purple Biotech Ltd. reported 1,806,089,801 Ordinary Shares outstanding. |
| 2025-12-31 | Date of event requiring the filing of this statement. |
| 2026-02-12 | Date the Schedule 13G was signed by Susquehanna Securities, LLC. |
Recommendation
holdThis filing is a routine disclosure of a passive ownership stake by an institutional investor and does not provide new fundamental information about Purple Biotech Ltd.'s operations, financial performance, or strategic direction. Therefore, it does not warrant a change in investment recommendation based solely on this report.
Keywords
Purple Biotech, Susquehanna Securities, Schedule 13G, Beneficial Ownership, Ordinary Shares, ADS, Biotech, Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.